The activities of Eisai Inc. in the United States are guided by our human health care (hhc) mission--to give first thoughts to patients and their families and to help increase the benefits that health care provides. An integral part of our hhc mission is to comply with all laws and regulations that govern our business and to achieve our corporate goals and implement our corporate mission on the basis of such compliance, and in accordance with the highest level of integrity.
Eisai Inc. observes general industry guidelines as set forth by the Pharmaceutical Research and Manufacturers of America (PhRMA), the Office of the Inspector General (OIG) and others as it relates to our work with healthcare professionals. For more information about these guidelines, please visit the following web sites.
Eisai Inc. supports the PhRMA Direct-to-Consumer (DTC) advertising recommendations as part of its commitment to educate the public about disease states and potential treatments so patients and their families can better understand healthcare options and communicate more effectively with healthcare professionals. For more information about these recommendations, visit the PhRMA web site.
Eisai is committed to clinical trial transparency and publicly discloses information about its qualifying studies on the NIH-sponsored website (www.clinicaltrials.gov).
Eisai's vision is to be recognized and respected as a responsible, focused, efficient, innovative and adaptive pharmaceutical company. As such, compliance with all relevant laws and regulations is a cornerstone of the company's existence.